logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

LUNG KEE (00255) issues 140,000 shares upon exercise of share options.

date
17:23 03/11/2026
avatar
GMT Eight
LUNG KEE (00255) announced that on November 3, 2026, 140,000 shares were issued upon the exercise of share options under the share option scheme adopted on September 28, 2023.
LUNG KEE (00255) announced that on November 3, 2026, 140,000 shares were issued upon the exercise of share options under the share option scheme adopted on September 28, 2023.
Related Articles
HK Stock
CAOCAO INC (02643) repurchased 60,000 shares for HK$586,300 on November 3.
HK Stock
Shenzhen Woer Heat-shrinkable Material (09981) repurchased 400,000 shares on November 3 for approximately HK$3.1013 million.
HK Stock
CSPC PHARMA (01093): Phase II clinical trial of SYH2072 tablets for the treatment of uncontrolled hypertension and resistant hypertension officially launched at the first research site in China
CAOCAO INC (02643) repurchased 60,000 shares for HK$586,300 on November 3.
HK Stock
Shenzhen Woer Heat-shrinkable Material (09981) repurchased 400,000 shares on November 3 for approximately HK$3.1013 million.
HK Stock
CSPC PHARMA (01093): Phase II clinical trial of SYH2072 tablets for the treatment of uncontrolled hypertension and resistant hypertension officially launched at the first research site in China
HK Stock
RECOMMEND
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
Why ATGL's Small Scale Could Become an Advantage in Enterprise AI
icon
25/09/2026
From IT Services to Enterprise AI: What ATGL Must Prove Next
From IT Services to Enterprise AI: What ATGL Must Prove Next
icon
24/09/2026
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
Anthony Tsang’s Strategic Control Could Be the Key to ATGL’s AI Transformation
icon
22/09/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.